Amedisys, Inc.
AMED
pitch
long
Ken Leslie
Thesis
The current AMED share price implies little to no revenue growth due to concerns over Medicare reimbursement reform. However, Amedisys is positioned for growth through acquisitions, a strong pipeline of startup agencies, and improved operational efficiencies. The company is expected to maintain or even expand margins, presenting a buying opportunity for investors.
Did it work?
failed
confidence: high
The long thesis anticipated growth in revenue and margins for Amedisys, but the stock has declined by 27.9% over the elapsed time of 203 months. This significant drop indicates that the expected growth and operational improvements did not materialize, leading to a failure of the investment thesis.
Raw excerpt
No raw excerpt stored.